Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects. • Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.